BR112023023894A2 - Método para tratar pacientes com síndrome hepatorrenal tipo 1 - Google Patents
Método para tratar pacientes com síndrome hepatorrenal tipo 1Info
- Publication number
- BR112023023894A2 BR112023023894A2 BR112023023894A BR112023023894A BR112023023894A2 BR 112023023894 A2 BR112023023894 A2 BR 112023023894A2 BR 112023023894 A BR112023023894 A BR 112023023894A BR 112023023894 A BR112023023894 A BR 112023023894A BR 112023023894 A2 BR112023023894 A2 BR 112023023894A2
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- type
- hepatorenal syndrome
- terlipressin
- treating patients
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 201000011200 hepatorenal syndrome Diseases 0.000 title abstract 3
- 108010010056 Terlipressin Proteins 0.000 abstract 3
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 abstract 3
- 229960003813 terlipressin Drugs 0.000 abstract 3
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract 2
- 101100205030 Caenorhabditis elegans hars-1 gene Proteins 0.000 abstract 1
- 206010057573 Chronic hepatic failure Diseases 0.000 abstract 1
- 208000010334 End Stage Liver Disease Diseases 0.000 abstract 1
- 206010062237 Renal impairment Diseases 0.000 abstract 1
- 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 abstract 1
- 208000011444 chronic liver failure Diseases 0.000 abstract 1
- 229940109239 creatinine Drugs 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000006213 oxygenation reaction Methods 0.000 abstract 1
- 231100000857 poor renal function Toxicity 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/340,765 US20210290725A1 (en) | 2014-10-24 | 2021-06-07 | Method of treating patients with hepatorenal syndrome type 1 |
| PCT/US2022/032511 WO2022261102A1 (en) | 2021-06-07 | 2022-06-07 | Method of treating patients with hepatorenal syndrome type 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023023894A2 true BR112023023894A2 (pt) | 2024-02-20 |
Family
ID=84426322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023023894A BR112023023894A2 (pt) | 2021-06-07 | 2022-06-07 | Método para tratar pacientes com síndrome hepatorrenal tipo 1 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4351619A1 (zh) |
| KR (1) | KR20240019089A (zh) |
| CN (1) | CN117425488A (zh) |
| AU (1) | AU2022288996A1 (zh) |
| BR (1) | BR112023023894A2 (zh) |
| CA (1) | CA3219851A1 (zh) |
| WO (1) | WO2022261102A1 (zh) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8628979B2 (en) * | 2009-10-21 | 2014-01-14 | Pronota N.V. | MCAM as a biomarker for fluid homeostasis |
| US20210000385A1 (en) * | 2014-04-11 | 2021-01-07 | Halare, Inc. | Systems, methods and apparatuses for monitoring hypoxic events |
| US20210290725A1 (en) * | 2014-10-24 | 2021-09-23 | Mallinckrodt Pharmaceuticals Ireland Limited | Method of treating patients with hepatorenal syndrome type 1 |
| US20200261443A1 (en) * | 2019-02-15 | 2020-08-20 | Martin Pharmaceuticals Inc. | Use of Anti-Ischemic Compounds in Treating Acute-On-Chronic Liver Failure |
| BR112022006329A2 (pt) * | 2019-10-30 | 2022-08-16 | Mallinckrodt Hospital Products IP Unlimited Company | Método de tratamento de pacientes com síndrome hepatorrenal tipo 1 e pressão arterial média baixa |
-
2022
- 2022-06-07 AU AU2022288996A patent/AU2022288996A1/en active Pending
- 2022-06-07 BR BR112023023894A patent/BR112023023894A2/pt unknown
- 2022-06-07 EP EP22820898.9A patent/EP4351619A1/en active Pending
- 2022-06-07 KR KR1020237040067A patent/KR20240019089A/ko unknown
- 2022-06-07 CA CA3219851A patent/CA3219851A1/en active Pending
- 2022-06-07 CN CN202280040420.5A patent/CN117425488A/zh active Pending
- 2022-06-07 WO PCT/US2022/032511 patent/WO2022261102A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240019089A (ko) | 2024-02-14 |
| EP4351619A1 (en) | 2024-04-17 |
| CN117425488A (zh) | 2024-01-19 |
| AU2022288996A1 (en) | 2023-11-30 |
| CA3219851A1 (en) | 2022-12-15 |
| WO2022261102A1 (en) | 2022-12-15 |
| AU2022288996A9 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kelly et al. | Short bowel syndrome: highlights of patient management, quality of life, and survival | |
| Knauf et al. | Dabigatran and kidney disease: a bad combination | |
| AR038113A1 (es) | Soluciones basadas en bicarbonato para terapia de dialisis | |
| Rottembourg et al. | Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice | |
| Leung et al. | A retrospective review of the use of regional citrate anticoagulation in continuous venovenous hemofiltration for critically ill patients | |
| Wei et al. | Early use of endotoxin absorption by oXiris in abdominal septic shock: A case report | |
| BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
| BR112023023894A2 (pt) | Método para tratar pacientes com síndrome hepatorrenal tipo 1 | |
| Rodríguez Santana et al. | Treatment of severe hypertriglyceridemia with continuous insulin infusion | |
| Cheng et al. | Comparison of the therapeutic effectiveness of sustained low-efficiency dialysis (SLED) with continuous blood purification (CBP) in critically ill patients | |
| Frass et al. | Two cases of fulminant hepatic failure from Amanita phalloides poisoning treated additively by homeopathy | |
| Ferreres et al. | Calciphylaxis associated with alcoholic cirrhosis | |
| Bajpai et al. | Role of high-volume plasma exchange in a case of a G6PD deficient patient presenting with HAV related acute liver failure and concomitant acute renal failure | |
| Bhattacharjee et al. | Early histopathologic changes in purple glove syndrome | |
| Papacostas et al. | Use of continuous renal replacement therapy in salicylate toxicity: a case report and review of the literature | |
| Al-Hashaykeh et al. | Delayed administration of antivenin three days after snake bite saves a life | |
| Larralde et al. | Calcinosis cutis following liver transplantation in a pediatric patient | |
| Carroll et al. | Treatment of the arthropathy of familial hypercholesterolaemia. | |
| Desuter et al. | Hydroxychloroquine as treatment for inflammatory subglottic stenosis: a second successful case | |
| West | Rhabdomyolysis associated with compartment syndrome resulting in acute renal failure | |
| Davidoss et al. | Extravasation of parenteral nutrition in the neck: A case report | |
| CN116440111A (zh) | 左甲状腺素钠在制备预防或治疗肝损伤药物中的应用 | |
| TRASLAZIONALE | Multi-arm randomized trial, comparing the efficacy of therapeutic strategies for at home early treatment of mild or moderate COVID-19 (SARS-CoV-2 infection) patients on the reduction of the risk of disease worsening | |
| Rudling | Increased synthesis of bile acids in gallstone disease is a global finding and not a “peculiar condition” solely in Chile | |
| Laursen et al. | Implementation of a coagulation component into a phosphate kinetics model in haemodialysis therapy: A tool for detection of clotting problems? |